Skip to main content
. Author manuscript; available in PMC: 2018 Jan 22.
Published in final edited form as: Curr Opin Rheumatol. 2016 Jul;28(4):359–367. doi: 10.1097/BOR.0000000000000301

Table 2.

Topics for future investigation in axSpA

  • The role of IL-23/IL-17 axis in new bone formation

  • Understanding the mechanisms by which the microbiome and ILC3 initiate and sustain gut and bone inflammation in axSpA

  • New knowledge about the types and functional importance of innate immune cells that express the IL-23R

  • Confirmation and further Investigation of the cellular and cytokine pathways responsible for the sexual dimorphism in axSpA

  • Strategies to Identify patients closer to time of disease onset focusing on markers in the IL-23/IL-17 pathway

  • Clinical trials examining additional targets in the IL-17 and IL-23 pathway

  • Development of stratification biomarkers to select and optimize treatment regimens